Peer review shows promising results of new vaccine against SARS CoV-2 virus

A paper in the New England Journal of Medicine reports on a trial of 45 healthy adults aged 18-55, each vaccinated twice, 28 days apart, with the mRNA-1273 vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) and pharmaceutical company Moderna. All participants subsequently produced antibodies against the SARS CoV-2 virus, and their blood serum showed neutralizing activity against the virus, preventing it from entering cells. Moreover, the vaccine appears to provide stronger protection against new infections than an average bout of actually catching the disease.

Link to paper:

Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study

A preprint of a study says that countries with mandatory policies to vaccinate against tuberculosis register fewer coronavirus deaths than countries that don’t have those policies.

Link to article:

NIH clinical trial of investigational vaccine for COVID-19 begins

March 17, 2020. A clinical trial of investigational vaccine for COVID-19 has begun.  Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. Currently (March 17, 2020) no approved vaccines exist to prevent infection with SARS-CoV-2.

Link to article:

Scroll to top